先声药业(02096.HK) 公布,与AbbVie Inc.(ABBV.US) 附属订立许可选择权协议,据此,AbbVie将拥有研究性新候选药物SIM0500的许可选择性权益。SIM0500正在中美两国针对复发或难治性多发性骨髓瘤患者进行临床I期研究。
集团将从AbbVie收取首付款,以及最高10.55亿美金的选择性权益付款和里程碑付款。同时,将额外获得基于该产品在大中华区以外地区净销售额的分级特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-13 16:25。) (美股为即时串流报价; OTC市场股票除外,资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.